Neffy epinephrine nasal spray demonstrates positive data in repeat dosing study
February 21st 2024ARS Pharma plans to submit data from the repeat dose study of neffy to the FDA early in the second quarter of 2024, as part of its response to the CRL issued by the federal agency for the previously submitted New Drug Application (NDA).